Czech Technical-UPenn-NYU Team Wins Grand Challenge in US$5-Million MBZIRC2020 Organized by Khalifa University
26.2.2020 17:14:00 EET | Business Wire | Press release
H.E. Dr. Mugheer Khamis Al Khaili, Member of the Executive Council, and Chairman of Department of Community Development today honored the Grand Challenge team winners Czech Technical University-University of Pennsylvania-NYU and winners of the three Challenge categories at the three-day US$5-million Mohamed Bin Zayed International Robotics Challenge (MBZIRC) 2020 that concluded in Abu Dhabi, organizers Khalifa University of Science and Technology announced today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200226005539/en/
Czech Technical-UPenn-NYU Team Wins Grand Challenge in US$5-Million MBZIRC2020 organized by Khalifa University (Photo: AETOSWire)
The winning teams in all three categories – Challenge 1, 2, and 3 – also received awards from H.E. Dr. Mugheer Khamis Al Khaili at the ceremony.
His Excellency Hussein Bin Ibrahim Al Hammadi, Steering Committee General Chair, MBZIRC 2020, Dr. Arif Sultan Al Hammadi, Steering Committee General Co-Chair, and His Excellency Dr. Mohammed Al Mualla, Steering Committee Member, were present.
Others who attended the ceremony included UAE government officials, Challenge partners, stakeholders from the academia, research, and industry, as well as all the MBZIRC 2020 team members.
The Czech Technical University-University of Pennsylvania-NYU team won the first position in the Grand Challenge. The University of Bonn team came second, while the combined team of Universidad Politecnica Madrid-Universidad Pablo Olvide Poznan University of Technology- Centre National de la Recherche Scientifique won the third place.
The Beijing Institute of Technology topped Challenge 1 category with the Czech Technical University-University of Pennsylvania-NYU team and the University of Tokyo in the second and third places, respectively, while the Czech Technical University-University of Pennsylvania-NYU team won the Challenge 2 category with Nimbro (University of Bonn) and Technical University of Denmark in the second and third places. Challenge 3 was won by University of Seville-Tecnico Lisboa-CATEC team, while the Technical University of Denmark and the University of New South Wales-Sydney tied for the second place.
The 32 finalists, representing 17 countries, were shortlisted out of 134 teams from across the globe that applied to compete in MBZIRC 2020.
Dr. Arif Sultan Al Hammadi said: “The second edition of MBZIRC has emphatically placed MBZIRC as one of the most prestigious competitions in robotics and artificial intelligence globally, while positioning Khalifa University as the leading higher education institution driving innovation in all areas of science, engineering, and newly-emerging technologies.”
Dr. Al Hammadi added: “Congratulations to all the winners of MBZIRC 2020, especially the Grand Challenge winner and winners of all three Challenge categories. However, all the participating teams deserve credit for their commitment, determination and perseverance during the competition, consistently raising the bar of excellence as displayed by various autonomous drones. Through this Challenge, we have witnessed how technology continues to evolve and we firmly believe the advancements demonstrated by these UAVs and UGVs will very soon become part of our everyday lives.”
For more information, please visit: http://www.ku.ac.ae/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005539/en/
Contact information
APCO Worldwide
Abdullah Al Sayed, Account Director, +971504887044
aalsayed@apcoworldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
